Improving cancer treatment through advanced imaging and therapy tools
Official title: Comprehensive Assessment of Cancer Theranostics Response
Funded at Aiq Solutions, INC. · NIH-10933574 · Data updated 2026-11-12
This study is working on new tools to help doctors better see and treat metastatic castration-resistant prostate cancer, using special imaging and therapy techniques that can give more accurate information about how well treatments are working and any side effects, making it easier for patients to get the best care possible.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Aiq Solutions, INC. NIH-funded |
| Lab location | 1 site (Madison, United States) |
| Project start | September 22, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $1,104,267 |
| NIH project number | 5R44CA285006-02 |
| Project ID | NIH-10933574 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who are undergoing treatment.
✕Less likely to help
Patients with early-stage prostate cancer or those not diagnosed with prostate cancer may not benefit from this research.
What this research studies
This research focuses on developing advanced imaging and therapeutic tools for patients with metastatic castration-resistant prostate cancer (mCRPC). By utilizing theranostics, which combines targeted diagnostic and therapeutic radionuclides, the project aims to enhance the assessment of tumor response and treatment-related toxicities. The approach involves creating automated software that can analyze molecular images more efficiently and accurately than current manual methods, allowing for better decision-making in patient care. This could lead to improved treatment outcomes by providing clinicians with critical information about tumor status and potential organ toxicity.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatment strategies for patients with advanced prostate cancer.
How similar studies have gone: Previous research has shown promise in using theranostics for cancer treatment, indicating that this approach could lead to significant advancements in patient care.
Where this research is happening
-
Aiq Solutions, INC.
Madison, United States Active
Researchers
- Principal investigator: Perk, Timothy — Aiq Solutions, INC.
- Study coordinator: Perk, Timothy
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.